First ALS patient shows sustained improvement after custom RNA therapy
A man with rare amyotrophic lateral sclerosis (ALS) experienced improved symptoms and maintained his career as a physician one year after receiving the first antisense oligonucleotide therapy targeting his specific genetic mutation. The treatment, delivered via spinal injection, reduced biomarkers of neuron damage to normal levels without serious side effects. Researchers describe this as a foundational step for treating neurodegenerative diseases caused by rare mutations, noting that the drug was developed in just three years compared to the decade-long timelines for common mutations.
